Product Description
Mechanisms of Action: NMDA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Neurotune AG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Peripheral Nervous System Diseases|HIV Infections|Acquired Immunodeficiency Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01444690 |
DIPANAP | P2 |
Unknown status |
Acquired Immunodeficiency Syndrome|HIV Infections |
2013-01-01 |
2019-03-19 |
Treatments |
|
NCT01135251 |
CRO-08-94/NT-11624/003 | P2 |
Completed |
Peripheral Nervous System Diseases |
2010-03-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/07/2021 |
News Article |
Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals |